Colorectal cancer screening and prevention

Jeff T Wilkins, Danielle McMechan, Asif Talukder

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Colorectal cancer is a common cause of morbidity and mortality in the United States. Most colorectal cancers arise from preexisting adenomatous or serrated polyps. The incidence and mortality of colorectal cancer can be reduced with screening of average-risk adults 50 to 75 years of age. Randomized controlled trials show evidence of reduced colorectal cancer–specific mortality with guaiac-based fecal occult blood tests and flexible sigmoidoscopy. There are no randomized controlled trials on the effectiveness of colonoscopy to reduce colorectal cancer–specific mortality; however, several randomized controlled trials comparing colonoscopy with other strategies are in progress. The best available evidence supporting colonoscopy is from prospective cohort studies that demonstrate decreased incidence of colorectal cancer and colorectal cancer–related mortality in individuals undergoing colonoscopy. Other screening options include fecal immunochemical testing, computed tomographic colonography, and multitargeted stool DNA testing combined with fecal immunochemical testing. There is good evidence that aspirin, nonsteroidal anti-inflammatory drugs, cyclooxygenase-2 inhibitors, and hormone therapy decrease the risk of colorectal cancer and adenomatous polyps, but potential harms limit their usefulness. There is good evidence that calcium supplementation, moderate dairy consumption, reduced red meat consumption, increased physical activity, decreased body mass index, and statin use decrease the risk of colorectal cancer and adenomatous polyps. Although increased alcohol intake and tobacco use are associated with an increased risk of colorectal cancer, there is no direct evidence that reducing alcohol consumption or smoking cessation decreases the risk.

Original languageEnglish (US)
Pages (from-to)658-665
Number of pages8
JournalAmerican family physician
Volume97
Issue number10
StatePublished - May 15 2018

Fingerprint

Early Detection of Cancer
Colorectal Neoplasms
Colonoscopy
Mortality
Adenomatous Polyps
Randomized Controlled Trials
Guaiac
Computed Tomographic Colonography
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Sigmoidoscopy
Occult Blood
Cyclooxygenase 2 Inhibitors
Incidence
Tobacco Use
Hematologic Tests
Smoking Cessation
Polyps
Alcohol Drinking
Aspirin
Body Mass Index

ASJC Scopus subject areas

  • Family Practice

Cite this

Wilkins, J. T., McMechan, D., & Talukder, A. (2018). Colorectal cancer screening and prevention. American family physician, 97(10), 658-665.

Colorectal cancer screening and prevention. / Wilkins, Jeff T; McMechan, Danielle; Talukder, Asif.

In: American family physician, Vol. 97, No. 10, 15.05.2018, p. 658-665.

Research output: Contribution to journalArticle

Wilkins, JT, McMechan, D & Talukder, A 2018, 'Colorectal cancer screening and prevention', American family physician, vol. 97, no. 10, pp. 658-665.
Wilkins JT, McMechan D, Talukder A. Colorectal cancer screening and prevention. American family physician. 2018 May 15;97(10):658-665.
Wilkins, Jeff T ; McMechan, Danielle ; Talukder, Asif. / Colorectal cancer screening and prevention. In: American family physician. 2018 ; Vol. 97, No. 10. pp. 658-665.
@article{e06dd042c9604830989b776e871a9f02,
title = "Colorectal cancer screening and prevention",
abstract = "Colorectal cancer is a common cause of morbidity and mortality in the United States. Most colorectal cancers arise from preexisting adenomatous or serrated polyps. The incidence and mortality of colorectal cancer can be reduced with screening of average-risk adults 50 to 75 years of age. Randomized controlled trials show evidence of reduced colorectal cancer–specific mortality with guaiac-based fecal occult blood tests and flexible sigmoidoscopy. There are no randomized controlled trials on the effectiveness of colonoscopy to reduce colorectal cancer–specific mortality; however, several randomized controlled trials comparing colonoscopy with other strategies are in progress. The best available evidence supporting colonoscopy is from prospective cohort studies that demonstrate decreased incidence of colorectal cancer and colorectal cancer–related mortality in individuals undergoing colonoscopy. Other screening options include fecal immunochemical testing, computed tomographic colonography, and multitargeted stool DNA testing combined with fecal immunochemical testing. There is good evidence that aspirin, nonsteroidal anti-inflammatory drugs, cyclooxygenase-2 inhibitors, and hormone therapy decrease the risk of colorectal cancer and adenomatous polyps, but potential harms limit their usefulness. There is good evidence that calcium supplementation, moderate dairy consumption, reduced red meat consumption, increased physical activity, decreased body mass index, and statin use decrease the risk of colorectal cancer and adenomatous polyps. Although increased alcohol intake and tobacco use are associated with an increased risk of colorectal cancer, there is no direct evidence that reducing alcohol consumption or smoking cessation decreases the risk.",
author = "Wilkins, {Jeff T} and Danielle McMechan and Asif Talukder",
year = "2018",
month = "5",
day = "15",
language = "English (US)",
volume = "97",
pages = "658--665",
journal = "American Family Physician",
issn = "0002-838X",
publisher = "American Academy of Family Physicians",
number = "10",

}

TY - JOUR

T1 - Colorectal cancer screening and prevention

AU - Wilkins, Jeff T

AU - McMechan, Danielle

AU - Talukder, Asif

PY - 2018/5/15

Y1 - 2018/5/15

N2 - Colorectal cancer is a common cause of morbidity and mortality in the United States. Most colorectal cancers arise from preexisting adenomatous or serrated polyps. The incidence and mortality of colorectal cancer can be reduced with screening of average-risk adults 50 to 75 years of age. Randomized controlled trials show evidence of reduced colorectal cancer–specific mortality with guaiac-based fecal occult blood tests and flexible sigmoidoscopy. There are no randomized controlled trials on the effectiveness of colonoscopy to reduce colorectal cancer–specific mortality; however, several randomized controlled trials comparing colonoscopy with other strategies are in progress. The best available evidence supporting colonoscopy is from prospective cohort studies that demonstrate decreased incidence of colorectal cancer and colorectal cancer–related mortality in individuals undergoing colonoscopy. Other screening options include fecal immunochemical testing, computed tomographic colonography, and multitargeted stool DNA testing combined with fecal immunochemical testing. There is good evidence that aspirin, nonsteroidal anti-inflammatory drugs, cyclooxygenase-2 inhibitors, and hormone therapy decrease the risk of colorectal cancer and adenomatous polyps, but potential harms limit their usefulness. There is good evidence that calcium supplementation, moderate dairy consumption, reduced red meat consumption, increased physical activity, decreased body mass index, and statin use decrease the risk of colorectal cancer and adenomatous polyps. Although increased alcohol intake and tobacco use are associated with an increased risk of colorectal cancer, there is no direct evidence that reducing alcohol consumption or smoking cessation decreases the risk.

AB - Colorectal cancer is a common cause of morbidity and mortality in the United States. Most colorectal cancers arise from preexisting adenomatous or serrated polyps. The incidence and mortality of colorectal cancer can be reduced with screening of average-risk adults 50 to 75 years of age. Randomized controlled trials show evidence of reduced colorectal cancer–specific mortality with guaiac-based fecal occult blood tests and flexible sigmoidoscopy. There are no randomized controlled trials on the effectiveness of colonoscopy to reduce colorectal cancer–specific mortality; however, several randomized controlled trials comparing colonoscopy with other strategies are in progress. The best available evidence supporting colonoscopy is from prospective cohort studies that demonstrate decreased incidence of colorectal cancer and colorectal cancer–related mortality in individuals undergoing colonoscopy. Other screening options include fecal immunochemical testing, computed tomographic colonography, and multitargeted stool DNA testing combined with fecal immunochemical testing. There is good evidence that aspirin, nonsteroidal anti-inflammatory drugs, cyclooxygenase-2 inhibitors, and hormone therapy decrease the risk of colorectal cancer and adenomatous polyps, but potential harms limit their usefulness. There is good evidence that calcium supplementation, moderate dairy consumption, reduced red meat consumption, increased physical activity, decreased body mass index, and statin use decrease the risk of colorectal cancer and adenomatous polyps. Although increased alcohol intake and tobacco use are associated with an increased risk of colorectal cancer, there is no direct evidence that reducing alcohol consumption or smoking cessation decreases the risk.

UR - http://www.scopus.com/inward/record.url?scp=85047080134&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047080134&partnerID=8YFLogxK

M3 - Article

VL - 97

SP - 658

EP - 665

JO - American Family Physician

JF - American Family Physician

SN - 0002-838X

IS - 10

ER -